Ares Commercial Real Estate Insider Shake‑Up: What Professionals Should Know This Week

Modern suburban homes

If your morning coffee pairs well with a dash of market intrigue, today’s spotlight lands squarely on Ares Commercial Real Estate Corporation (NYSE:ACRE). The company’s CEO & Director, Bryan Donohoe, recently sold US$107k worth of shares at an average price of US$4.93—a move that trimmed his personal stake by roughly 13%.

Insider activity doesn’t always spell trouble, but it always sparks questions. And in today’s evolving market landscape, Florida real estate agents, mortgage professionals, and investment‑minded specialists nationwide should keep an eye on moves like these. Understanding market behavior is part of staying competitive—something we take seriously at Cameron Academy as we help professionals stay informed, licensed, and ahead of industry shifts.

A Bigger Pattern? Understanding ACRE Insider Behavior

This isn’t Donohoe’s first sale of the year. Earlier, he sold approximately US$133k worth of shares at US$5.68 per share—meaning his earlier sale happened at a stronger price point. While insider selling is common, repeated sales without any insider buying can raise eyebrows among seasoned investors.

According to the data, insiders at Ares Commercial Real Estate made no purchases in the past 12 months. That doesn’t automatically signal danger, but it does create a tone of caution from within the leadership ranks.

See the Full Insider Activity Chart

Want to explore every insider transaction from the past year? View the interactive chart here and dig into dates, prices, and individual trades.

How Much Skin Do Insiders Have in the Game?

Insider ownership sits at about 1.6%—worth roughly US$4.6 million. While not insignificant, it isn’t especially high either. Lower insider ownership often correlates with lower long-term alignment, though it doesn’t always indicate poor performance.

As the Simply Wall St analysis suggests, many companies show stronger internal confidence through larger insider holdings. ACRE’s numbers are conservative but not alarming.

What Should Professionals Take Away?

Insiders sold stock recently, and none showed buying activity. Combined with modest insider ownership, the indicators suggest a measured caution. Still, insider selling by itself is not a forecast of decline—it’s simply one piece of a much larger market puzzle.

For professionals navigating real estate, finance, and investment spaces, this serves as a reminder of the importance of market literacy. Whether you’re evaluating REITs, shaping a portfolio, or watching economic signals, staying informed is essential. If you’re growing your career or expanding your license portfolio, Cameron Academy provides the educational backbone to help keep you competitive and current.

More From the Source

Explore the full analysis, discover small-cap stocks insiders are buying, or try their free portfolio tools:

Insider‑Bought Small Caps
Try the Free Portfolio Companion
Contact the Editorial Team

And as always: this information isn’t financial advice—but it does help you stay sharp, curious, and one step ahead as you navigate the day’s headlines.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Is Florida’s Booming Real Estate Market Becoming Unaffordable?

Florida is facing a real estate crisis marked by skyrocketing insurance premiums, stringent FEMA rules, and a surge in hedge fund property acquisitions.

By |November 14, 2024|Categories: Article, Finance/Economy, Real Estate|Tags: , |0 Comments

Revolutionizing Cancer Therapy: The Promise of Patient-Derived Organoids

Patient-derived organoids offer an unprecedented opportunity to replicate the complex structure and genetic makeup of cancers, providing a more accurate model for clinical drug screening and pharmacognostic assessment.

The AI Revolution in Dermatology: A Systematic Review

In a groundbreaking study published in Nature, researchers have delved into the burgeoning field of artificial intelligence (AI) in dermatology, specifically examining its role in diagnosing skin cancer. The study, titled "A Systematic Review and Meta-Analysis of Artificial Intelligence Versus Clinicians for Skin Cancer Diagnosis," offers a comprehensive look at how AI stacks up against human clinicians in this critical area of healthcare.

By |November 14, 2024|Categories: AI in Healthcare, Article, Dermatology|Tags: , |0 Comments

The Fast Lane to Fully Autonomous Vehicles: Industry Innovations and Future Prospects

The automotive world is abuzz with announcements from major players like Tesla, Rimac, Renault, and Nissan, each unveiling plans to introduce autonomous vehicles in the near future. Tesla's much-anticipated "CyberCab" is set for an October 2024 debut, while Rimac and Renault are gearing up for releases in 2026.

Futureproofing for Insurers: The Role of AI and Hyper-Personalization

In a rapidly evolving industry, insurance companies are turning to artificial intelligence (AI) and hyper-personalization to stay ahead of the curve.

Revolutionizing Healthcare: The Power and Potential of AI

AI technology offers a multitude of benefits, from enhancing patient outcomes to reducing healthcare costs and improving population health. Its application ranges from preventive screenings to complex diagnostic procedures, marking a new era in medical care.

By |November 13, 2024|Categories: Article, Artificial Intelligence, Healthcare|Tags: , |0 Comments